OC-081 Defining Cirrhosis with Fibroscan for entry to Hepatocellular Carcinoma Surveillance in Chronic Hepatitis C: a UK Cost Effectiveness Analysis

摘要: Introduction Chronic hepatitis C (HCV) is a significant risk factor for cirrhosis and subsequently hepatocellular carcinoma (HCC). HCV patients with are screened HCC every 6 months. Surveillance progression to cirrhosis, consequently access screening, not standardised. Liver biopsy, the usual test determine carries of morbidity. Ultrasound elastography (Fibroscan) non-invasive cirrhosis. This study assesses cost effectiveness annual surveillance in chronic effect replacing biopsy fibroscan diagnose Methods A Markov decision analytic model simulated hypothetical cohort 10000 initially without fibrosis over their lifetime. Cirrhosis strategies assessed were: (A) no surveillance; (B) current practise; (C) practise confirm cirrhosis; (D) completely (definitive); (E) biopsy; (F) (G) definitive fibroscan. Results The was calibrated good visual fit. Annual optimal strategy choice. Sensitivity analysis shows this outcome be robust. cost-effective frontier holds G E dominated by extension. All other strictly dominated. It diagnoses 20% more than strategy, 549 extra per accessing screening lifetime; 76 additional HCCs diagnosed. Lifetime an £98.78 patient compared 1.72 unadjusted life years. 132 one ICER £6557.06/QALY gained. Conclusion may identify allow screening. Disclosure Interest None Declared